Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FAS–41BB Switch Receptor (FAS–41BB IFP)
- Target
- FAS–41BB IFP
- Molecular classification
- Fusion Protein, Chimeric Receptor, Immunomodulatory Fusion Protein (IFP)
01
Overview
The FAS–41BB switch receptor is a synthetic immunomodulatory fusion protein designed to enhance the function and persistence of adoptively transferred T cells. It combines the extracellular domain of Fas (CD95) with the intracellular signaling domain of 4-1BB (CD137). By binding to FasL in the tumor microenvironment, it converts a pro-apoptotic signal into a pro-survival and costimulatory signal, boosting T cell effector functions and overcoming tumor-induced immunosuppression.
- Other names
- Fas-41BB Fusion ProteinFAS-CD137 chimeric receptorFAS-41BB IFP
02
Mechanism of action
Converts pro-apoptotic signal from FasL into a pro-survival and costimulatory signal via 4-1BB, enhancing T cell proliferation, survival, metabolic fitness, and antitumor activity.
03
Biological functions
CostimulationT cell activationEnhanced T cell survivalIncreased T cell proliferationAntitumor activityImmune modulation
04
Disease associations
CancerSolid TumorsKRAS-mutant cancersImmunosuppression
05
Safety considerations
Potential for off-target effects, although restricted to genetically modified T cellsImmunogenicity of the fusion protein
06
Interacting drugs
AFNT-211 (TCR-T therapy co-expressing HLA-A*11:01 KRAS G12V-specific TCRs with CD8α/β coreceptor and FAS–41BB switch receptor)
07
Biomarkers
FasL expression in tumor microenvironmentKRAS G12V mutation
Beyond the preview
Go deeper on FAS–41BB Switch Receptor (FAS–41BB IFP).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FAS–41BB Switch Receptor (FAS–41BB IFP).